524500 logo

Kilitch Drugs (India) Limited Stock Price

BSE:524500 Community·₹5.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

524500 Share Price Performance

₹350.65
22.70 (6.92%)
₹350.65
22.70 (6.92%)
Price ₹350.65

524500 Community Narratives

There are no narratives available yet.

Recent 524500 News & Updates

Kilitch Drugs (India) Limited Key Details

₹2.1b

Revenue

₹1.1b

Cost of Revenue

₹965.0m

Gross Profit

₹681.1m

Other Expenses

₹283.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
Earnings per share (EPS)
17.65
Gross Margin
46.39%
Net Profit Margin
13.65%
Debt/Equity Ratio
24.7%

Kilitch Drugs (India) Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Solid track record with excellent balance sheet.

1 Risk
2 Rewards

About 524500

Founded
1978
Employees
187
CEO
Mukund Mehta
WebsiteView website
kilitch.com

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
The market is up 1.5% over the last week, with the Financials sector leading the way, up 2.3%. In contrast, the market has seen a decline of 4.7% over the last 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›